# A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both

Study · id `cardio:ct-nct07931547` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07931547](<https://clinicaltrials.gov/study/NCT07931547>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07931547

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 450 participants.

## Technical summary

Registry record NCT07931547. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-10 (anticipated); primary completion 2028-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 450 participants (planned count; ClinicalTrials.gov record NCT07931547, source copy `cardio:ctgov-nct07931547-2026-11-12`, retrieved 2026-11-18)
- Planned start: 2026-11-10 (anticipated) (ClinicalTrials.gov record NCT07931547, source copy `cardio:ctgov-nct07931547-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2028-07-31 (anticipated) (ClinicalTrials.gov record NCT07931547, source copy `cardio:ctgov-nct07931547-2026-11-12`, retrieved 2026-11-18)
- Completion: 2028-09-25 (anticipated) (ClinicalTrials.gov record NCT07931547, source copy `cardio:ctgov-nct07931547-2026-11-12`, retrieved 2026-11-18)
- Countries: United States; Brazil; China; Czechia; Germany; India; Japan; Poland; South Korea; Türkiye (ClinicalTrials.gov record NCT07931547, source copy `cardio:ctgov-nct07931547-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07931547-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both
- Acronym: AMBITION 2
- Condition: Type 2 Diabetes
- Condition: Chronic Kidney Disease
- Intervention (Other): Placebo
- Intervention (Drug): Zenagamtide
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: a8a1f6afc484315789432cac114d81dec53bcfbc6edda30fa0807d3b545ffff6
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
